Immunotherapy Inspired Design for Artificial Immune Modulation (AIM)
Artificial Immune Modulations for Various Indications
Clinical Trial Insight for AIM: 3 Drugs
Expected Price Range for AIM Therapy: > US$ 250,000
Market Potential During Five Years of Commercialization: > USD 500 Million
Estimated Commercial Opportunity for Artificial Immune Modulation Drugs
Future Directions for Artificial Immune Modulation
The research report “Artificial Immune Modulation Therapy Market Opportunity and Clinical Trials Insight 2026” provides comprehensive insight on the applications of artificial immune modulation therapy in today’s cancer centric treatment methodologies. This report is focused towards introducing the therapy and the cells that are contributing to the therapy in an elaborated way. Report also discusses about the successful pre-clinical stage results of the therapy and information about its entry in the clinical trial landscape. The research report gives information about the growing interest of the researchers as well as companies towards the possible achievements that the therapy will face in the next few years.
Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at global level. As every immunotherapy technology focuses on one major part of immune system, AIM technology’s working is also based on artificial antigen presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen presenting cells to the patients which further is projected to mimic the core functions of natural antigen presenting cells present inside the human body.
The primary purpose with which artificial antigen presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and immune system.
An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of immune system against one target which includes the activation of specific types (antigen presenting cells and T-cells) in order to evoke a powerful immune response against specific antigen. It has been few decades since the development of immunotherapy for diseases in which immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.
As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing a data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.
Although the price of the therapy has not been decided yet but it has been estimated that the therapy will cost approximately the same as the other cancer immunotherapies. The therapy being novel is considered as a fast-growing method in the entire pharmaceutical industry. The therapy is still very young and is evaluated for causing a potential growth, substantive translational and clinical improvements. By observing the future outlook of the cancer cases and the current research activity, it is estimated that the market of AIM will undergo tremendous advancement leading towards the revolution of cancer therapeutics.
Figure 6-6: US – Clinical Trial Status for Artificial Immune Modulation, 2020
Figure 6-7: US – Multiple Myeloma Cancer Statistics, 2020
Figure 6-8: US – Multiple Myeloma Cancer Statistics by Gender, 2020
Figure 6-9: US – Clinical Trial Status for Artificial Immune Modulation
Figure 7-1: Recent Trends and Opportunity for Artificial Immune Modulation Growth
Figure 7-2: Global – Total New Cases of Cancers (Million), 2018
Figure 7-3: Global - Total Cancer Deaths (Million), 2018
Figure 7-4: Global – New Cases of Multiple Myeloma, 2018
Figure 7-5: Global – Total Deaths Due to Multiple Myeloma, 2018
Figure 7-6: Clinical Benefits of using Cancer Immunotherapy
Figure 7-7: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 7-8: US – Active, Not Recruiting Clinical Trials for Immunotherapy vs. Other Cancer Treatment Methods, 2020
Figure 7-9: Pharmaceutical Companies Investing in Immunotherapy Development
Figure 7-10: Global - Roche’s Total Immunological Products Sales (US$ Million), 2015 - 2019
Figure 7-11: Global – Roche Group Sales Increment (%), 2016 - 2019
Figure 7-12: Global – Eli Lilly’s Total Immunological Product Sales (US$ Million), 2017 - 2019
Figure 7-13: Global – Eli Lilly’s Increase in Immunology Revenue due to Taltz (%), 2018 and 2019
Figure 7-14: Potential Combinations for Artificial Immune Modulation
Figure 8-1: Global – CAR-T Cell Therapy Drug Kymriah Treatment Cost vs. Drug Cost (US$ Million), 2020
Figure 8-2: US – Price of CAR-T Cell Therapy Products (US$), 2020
Figure 8-3: Global – Kymriah Total Sales (US$ Million), 2018 and 2019
Figure 8-4: Global – Yescarta Total Sales (US$ Million), 2018 and 2019
Figure 8-5: US – TIL Immunotherapy Minimum and Maximum Treatment Price (US$), 2020
Figure 8-6: Immunotherapy Price Comparison
Figure 8-7: AIM Therapy – Minimum and Maximum Treatment Price Estimates (US$), 2026
Figure 9-1: Cancer Driver for Artificial Immune Modulation Market
Figure 9-2: Potential Drivers for Artificial Immune Modulation
Figure 9-3: Challenges Associated with Artificial Immune Modulation
Figure 10-1: US – Estimated Cancer Care Expenditure by Healthcare (US$ Billion), 2019 and 2026
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.